Clinical immunology - Autoimmunity in the Netherlands

Immunology Letters

Volumn 162, Issue 2, 2014, Pages 134-140

  Tervaert, Jan Willem Cohen ^a,c   Kallenberg, Cees G M ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Noordoever Academy Sint Franciscus Gasthuis   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA; MPO; PR3; SLE; Vasculitis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; HIGH MOBILITY GROUP B1 PROTEIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; APOPTOSIS; AUTOIMMUNITY; CLINICAL FEATURE; CLINICAL IMMUNOLOGY; HISTORY OF MEDICINE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; NETHERLANDS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; ANIMAL; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; HISTORY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY;

ALLERGY AND IMMUNOLOGY; ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NETHERLANDS;

EID: 84912105289     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.10.008     Document Type: Review

References (83)

1. Lisnevskaia L., Murphy G., Isenberg D. Systemic lupus erythematosus. Lancet 2014, pii:S0140-6736(14)60128-8. 10.1016/S0140-6736(14)60128-8.
2. Tsokos G.C. Systemic lupus erythematosus. N Engl J Med 2011, 365:2110-2121.
3. Deng Y., Tsao B.P. Advances in lupus genetics and epigenetics. Curr Opin Rheumatol 2014, (5):482-492.
4. Pieterse E., van der Vlag J. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol 2014, 5(April):164. 10.3389/fimmu.2014.00164.
5. Dieker J.W., Fransen J.H., van Bavel C.C., et al. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum 2007, 56:1921-1933.
6. van Bavel C.C., Dieker J.W., Kroese Y., et al. Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus. Ann Rheum Dis 2011, 70:201-207.
7. Reefman E., Horst G., Dijk M.T., Limburg P.C., Kallenberg C.G.M., Bijl M. Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fc-gamma receptor-dependent mechanism. Arthritis Rheum 2007, 56:3399-3411.
8. Reefman E., Kuiper H., Limburg P.C., Kallenberg C.G.M., Bijl M. Type 1 interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythematosus patients. Ann Rheum Dis 2008, 67:11-18.
9. Crow M.K. Type 1 interferon in the pathogenesis of lupus. Curr Opin Rheumatol 2014, (5):467-474. 10.1097/BOR.0000000000000087.
10. Ding H.J., Gordon C. New biologic therapy for systemic lupus erythematosus. Curr Opin Pharmacol 2013, 13:405-412.
11. Harris H.E., Andersson U., Pisetsky D.S. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012, 8:195-202.
12. Schaper F., Westra J., Bijl M. Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus. Mol Med 2014, 20:72-79.
13. Abdulahad D.A., Westra J., Bijzet J., et al. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relationship to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R71.
14. Schaper F., Heeringa P., Bijl M., Westra J. Inhibition of high-mobility group box 1 as therapeutic option in autoimmune disease: lessons from animal models. Curr Opin Rheumatol 2013, 25:259-269.
15. ter Borg E.J., Horst G., Hummel E.J., Limburg P.C., Kallenberg C.G. Measurement of increases in anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum 1990, 33:634-643.
16. Kramers C., Hylkema M.N., van Bruggen M.C., et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 1994, 94:568-577.
17. van der Vlag J., Berden J.H. Lupus Nephritis: role of antinucleosome autoantibodies. Semin Nephrol 2011, 31:376-389.
18. Coremans I.E., Spronk P.E., Bootsma H., et al. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 1995, 595-601.
19. Trouw L.A., Groeneveld T.W., Seelen M.A., et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004, 114:679-688.
20. de Groot P.G., Urbanus R.T. The significance of autoantibodies against β2-glycoprotein 1. Blood 2012, 120:266-274.
21. de Groot P.G. Mechanisms of anti-phospholipid antibody formation and action. Thromb Res 2011, 127(Suppl. 3):S40-S42.
22. Derksen R.H., de Groot P.G. Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus 2010, 19:470-474.
23. Dolff S., Bijl M., Huitema M.G., et al. Disturbed Th1, Th2, Th17 and Treg balance in patients with systemic lupus erythematosus. Clin Immunol 2011, 141:197-204.
24. Dolff S., Abdulahad W.H., van Dijk M.C., et al. Urinary T cells in active lupus nephritis show an effector memory phenotype. Ann Rheum Dis 2010, 69:2034-2041.
25. Steens S.C., Admiraal-Behloul F., Bosma G.P., et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum 2004, 50:2877-2881.
26. Emmer B.J., Steup-Beekman G.M., Steens S.C., et al. Correlation of magnetization transfer ratio histogram parameters with neuropsychiatric systemic lupus erythematosus criteria and proton magnetic resonance spectroscopy: association of magnetization transfer ratio peak height with neuronal and cognitive dysfunction. Arthritis Rheum 2008, 58:1451-1457.
27. Grootscholten C., Ligtenberg G., Hagen E.C., et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006, 70:732-742.
28. Arends S., Grootscholten C., Derksen R.H., et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 2012, 71:966-973.
29. Wallace D.J., Kalunian K., Petri M.A., et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phade IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014, 73:183-190.
30. Furie R., Petri M., Zamani O., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930.
31. Holvast A., Huckriede A., Wilschut J., et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006, 65:913-918.
32. Holvast A., van Assen S., de Haan A., et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009, 60:2438-2447.
33. van Assen S., Holvast A., Benne C.A., et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010, 62:75-81.
34. van Assen S., Agmon-Levi N., Elkayam O., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.
35. de Leeuw K., Freire B., Smit A.J., et al. Traditional and non-traditional risk factors contribute to the development of accelerated artherosclerosis in patients with systemic lupus erythematosus. Lupus 2006, 15:675-682.
36. de Leeuw K., Smit A.J., de Groot E., et al. Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. Atherosclerosis 2009, 206:546-550.
37. Westerweel P.E., Luyten R.K., Koomans H.A., et al. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007, 56:1384-1396.
38. Bultink I.E., Lems W.F., Kostense P.J., et al. Prevalence and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005, 52:2044-2050.
39. Cohen Tervaert J.W., Damoiseaux J. Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?. Clin Rev Allergy Immunol 2012, 43:211-219.
40. van der Woude F.J., Arisz L., Meijer S., Donker A.J., Hoedemaeker P.J., van Overbeek J.J. Wegener's granulomatosis. A clinicopathological study in twelve patients. Neth J Med 1978, 21(5):205-220.
41. Van der Woude F., Lobatto S., Permin H., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985, 325:425-429.
42. Goldschmeding R., Vanderschoot C.E., Tervaert J.W.C., Mason D.Y., Von dem Borne A.E.G.K., Kallenberg C.G.M. Autoantibodies against myeloid lysosomal-enzymes - a novel class of autoantibodies associated with vasculitic syndromes. Kidney Int 1988, 34:558-559.
43. Goldschmeding R., van der Schoot C.E., ten Bokkel Huinink D., Hack C.E., van den Ende M.E., Kallenberg C.G., et al. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989, 84(November (5)):1577-1587.
44. Tervaert J.W.C., Goldschmeding R., Hene R.J., Kallenberg C.G.M. Neutrophil cytoplasmic autoantibodies and Wegener's granulomatosis. Lancet 1989, 333:270.
45. Cohen Tervaert J., Goldschmeding R., Elema J., et al. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990, 37:799-806.
46. Cohen Tervaert J.W., Elema J., Kallenberg C. Clinical and histopathological association of 29kD-ANCA and MPO-ANCA. APMIS Suppl 1990, 19:35.
47. Cohen Tervaert J.W., Goldschmeding R., Elema J., et al. Anti-myeloperoxidase antibodies in the Churg-Strauss syndrome. Thorax 1991, 46:70-71.
48. Cohen Tervaert J.W., Limburg P., Elema J., et al. Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med 1991, 91:59-66.
49. Franssen C., Stegeman C., Kallenberg C., et al. Antiproteinase 3-and antimyeloperoxidase-associated vasculitis. Kidney Int 2000, 57:2195-2206.
50. Lyons P., Rayner T., Trivedi S., Genetically Distinct Subsets within ANCA-Associated Vasculitis, et al. N Engl J Med 2012, 367:214-223.
51. Tervaert J.W., van der Woude F.J., Fauci A.S., et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989, 149:2461-2465.
52. Tervaert J.W., Huitema M.G., Hené R.J., et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990, 336:709-711.
53. Boomsma M.M., Stegeman C.A., van der Leij M.J., et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000, 43:2025-2033.
54. Tomasson G., Grayson P.C., Mahr A.D., Lavalley M., Merkel P.A. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - a meta-analysis. Rheumatology (Oxford) 2012, 51:100-109.
55. Kemna M., Damoiseaux J., Austen J., Winkens B., Peters J., van Paassen P., et al. ANCA as a predictor of a relapse: useful in patients with renal involvement but not in patients with non-renal disease. J Am Soc Nephrol 2014, 10.1681/ASN.2013111233.
56. Ciavatta D., Yang J., Preston G., et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest 2010, 120:3209-3219.
57. Ben-Smith A., Dove S., Martin A., et al. Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcg receptor ligation. Blood 2001, 98:1448-1455.
58. van Timmeren M.M., Heeringa P. Pathogenesis of ANCA-associated vasculitis: recent insights from animal models. Curr Opin Rheumatol 2012, 24(January (1)):8-14.
59. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963.
60. Huugen D., Xiao H., Van Esch A., et al. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005, 167:47-58.
61. Little M.A., Smyth C., Yadav R., et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005, 106:2050-2058.
62. Van der Geld Y., Hellmark T., Selga D., et al. Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis 2007, 66:1679-1682.
63. Little M.A., Al-Ani B., Ren S., et al. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS ONE 2012, 7:e28626.
64. Stegeman C., Cohen Tervaert J.W., Kallenberg C. Nasal carriage of staphylococcal infection in Wegener granulomatosis. Ann Internal Med 1994, 120(1):12-17.
65. Popa E.R., Stegeman C.A., Bos N.A., Kallenberg C.G., Tervaert J.W. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999, 103(May (5 Pt 1)):885-894.
66. Wilde B., Thewissen M., Damoiseaux J., Knippenberg S., Hilhorst M., van Paassen P., et al. Regulatory B cells in ANCA-associated vasculitis. Ann Rheum Dis 2013, 72(August (8)):1416-1419.
67. + T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2007, 56(June (6)):2080-2091.
68. Wilde B., Hua F., Dolff S., Jun C., Cai X., Specker C., et al. Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. Rheumatology (Oxford) 2012, 51(July (7)):1188-1197.
69. Wilde B., Thewissen M., Damoiseaux J., Hilhorst M., van Paassen P., Witzke O., et al. Th17 expansion in granulomatosis with polyangiitis (Wegener's): the role of disease activity, immune regulation and therapy. Arthritis Res Ther 2012, 14(October (5)):R227.
70. Wilde B., Thewissen M., Damoiseaux J., van Paassen P., Witzke O., Tervaert J.W. T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?. Arthritis Res Ther 2010, 12(1):204.
71. Jayne D.R., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36-44.
72. Jones R., Cohen Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
73. Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
74. Cohen Tervaert J.W. Rituximab in ANCA-associated vasculitis: a revolution?. Nephrol Dial Transplant 2011, 26:3077-3079.
75. De Joode A.A., Sanders J.S., Smid W.M., Stegeman C.A. Plasmapheresis rescue therapy in progressive systemic ANCA-associated vasculitis: single-center results of stepwise escalation of immunosuppression. J Clin Apher 2014, February. [Epub ahead of print]. 10.1002/jca.21318.
76. Wilde B., Van Paassen P., Witzke O., et al. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011, 79:599-612.
77. Huugen D., Van Esch A., Xiao H., et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007, 71:646-654.
78. Hilhorst M., Wilde B., Van Paassen P., et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 2013, 28:373-379.
79. De Joode A., Sanders J., Stegeman C.A. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013, 8:1709-1717.
80. Drooger J.C., Dees A., Swaak A.J. ANCA-positive patients: the influence of PR3 and MPO antibodies on survival rate and the association with clinical and laboratory characteristics. Open Rheumatol J 2009, 3(March):14-17.
81. Cohen Tervaert J.W. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol 2013, 27:33-44.
82. Stassen P., Derks R., Kallenberg C., et al. Venous thromboembolism in ANCA-associated vasculitis-incidence and risk factors. Rheumatology 2008, 47:530-534.
83. Hilhorst M., Winckers K., Wilde B., et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol 2013, 40:2042-2046.